WD Rutherford LLC Buys 12,191 Shares of Boston Scientific Corporation $BSX

WD Rutherford LLC boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 53.4% in the fourth quarter, Holdings Channel reports. The firm owned 35,040 shares of the medical equipment provider’s stock after purchasing an additional 12,191 shares during the quarter. WD Rutherford LLC’s holdings in Boston Scientific were worth $3,341,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Requisite Capital Management LLC bought a new position in Boston Scientific during the fourth quarter worth about $458,000. RiverFront Investment Group LLC lifted its stake in Boston Scientific by 0.7% during the fourth quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider’s stock worth $2,032,000 after purchasing an additional 150 shares during the period. Passumpsic Savings Bank bought a new position in Boston Scientific during the fourth quarter worth about $3,141,000. North Dakota State Investment Board bought a new position in Boston Scientific during the fourth quarter worth about $4,826,000. Finally, Elyxium Wealth LLC lifted its stake in Boston Scientific by 4.4% during the fourth quarter. Elyxium Wealth LLC now owns 5,283 shares of the medical equipment provider’s stock worth $504,000 after purchasing an additional 221 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $52.67 on Monday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The firm has a market cap of $78.27 billion, a P/E ratio of 22.04, a P/E/G ratio of 0.97 and a beta of 0.62. The firm has a 50 day simple moving average of $63.40 and a 200 day simple moving average of $81.65. Boston Scientific Corporation has a fifty-two week low of $52.52 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of analyst reports. Raymond James Financial restated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a report on Monday, February 2nd. TD Cowen dropped their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Wells Fargo & Company dropped their price objective on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a report on Thursday, April 23rd. Finally, UBS Group dropped their price objective on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.